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Acivicin, a modified amino acid natural product, is a glutamine analog. Thus, it might interfere with
metabolism by hindering glutamine transport, formation, or usage in processes such as transamidation and
translation. This molecule prevented the growth of Escherichia coli in minimal medium unless the medium was
supplemented with a purine or histidine, suggesting that the HisHF enzyme, a glutamine amidotransferase,
was the target of acivicin action. This enzyme, purified from E. coli, was inhibited by low concentrations of
acivicin. Acivicin inhibition was overcome by the presence of three distinct genetic regions when harbored on
multicopy plasmids. Comprehensive transcript profiling using DNA microarrays indicated that histidine
biosynthesis was the predominant process blocked by acivicin. The response to acivicin, however, was quite
complex, suggesting that acivicin inhibition resonated through more than a single cellular process.
Interconnections among biochemical pathways remain an
understudied question in modern biology. Currently, this prob-
lem is being addressed in several different bacterial systems.
For example, Frodyma et al. (28) and Tsang et al. (77) inves-
tigated the metabolic integration (23) of vitamin synthetic
pathways which are thought to have a rather low flux since
cofactors are used in catalytic rather than structural quantities.
We have chosen to explore metabolic integration by focusing
on the action of an inhibitor, acivicin (Fig. 1), since it is be-
lieved to interact with glutamine amidotransferases (61, 62, 74,
84) and its antibacterial activity toward Bacillus subtilis is an-
tagonized by histidine and purine nucleosides (35). These en-
zymes extract ammonia from glutamine prior to attaching it to
an organic backbone.
In Escherichia coli there are at least 12 distinct glutamine
amidotransferases (58, 83) involved in biosynthesis, underscor-
ing the importance of ammonia assimilation by processes in
addition to transamination. Five are involved in amino acid
biosynthesis: anthranilate synthase (EC 4.1.3.27, TrpE), aspar-
agine synthase (EC 6.3.5.4, AsnB), carbamoyl phosphate syn-
thetase (EC 6.3.5.5, CarAB [used in arginine as well as pyrimi-
dine nucleotide production]), glutamate synthase (EC 1.4.1.13,
GltBD), and imidazole glycerol phosphate (IGP) synthase
(HisHF). Along with CarAB, another four (EC 6.3.4.2, PyrG,
CTP synthetase; EC 2.4.2.14, PurF, glutamine 5-phospho-D-
ribosyl-a-1-pyrophosphate [PRPP] amidotransferase; EC 6.3.5.3,
PurL, 5’-phosphoribosyl-N-formyl glycinamide [FGAM] syn-
thetase; and EC 6.3.4.1, GuaA, GMP synthetase) are enzymes
of nucleotide biosynthesis. Two, PabAB (4-amino-4-deoxychoris-
mate synthase, a component of the folate pathway) and NadE
(EC 6.3.5.1, NAD synthetase), function in cofactor synthesis,
while one, GlmS (EC 2.6.1.13), is involved in production of the
cell wall precursor N-acetylglucosamine phosphate. Thus, antag-
onism of this enzyme family might be most revealing.
One glutamine amidotransferase, IGP synthase, is encoded
by hisH and hisF; these two genes are components of the
histidine operon, hisGDCBHAFI (Fig. 2A) (88). This amido-
transferase occupies a central position in the eight-enzyme
pathway from PRPP and ATP to histidine (Fig. 3). If this
reaction or the immediately preceding HisA (pro-phosphori-
bosyl formimino-5-aminoimidazole-4-carboxamide ribonucle-
otide [PROFAR] isomerase)-catalyzed reaction is blocked,
ATP is still condensed with PRPP and undergoes subsequent
modification, including opening of its six-membered ring. Such
blockages drain the purine nucleotide pools, effectively causing
the metabolic economy to grind to a halt due to a lack of
“currency,” presumably in the form of adenylates. Normally
the amidotransferase reaction of the histidine biosynthetic
pathway liberates 5-aminoimidazole-4-carboxamido-1-b-D-
ribofuranosyl 59-monophosphate (AICAR) as a by-product.
The latter molecule, a purine biosynthetic intermediate, is sal-
vaged in a process that leads to the resynthesis of ATP. This
combined histidine-purine cycle is hence critical for cellular
function, as demonstrated by the studies of Hartman et al.
(36), Shedlovsky and Magasanik (70, 71), Johnston and Roth
(44), and Taylor et al. (29, 42, 72, 73). Moreover, overproduc-
tion of HisHF has other deleterious consequences for cell
division (3, 27, 57) independent of the above-mentioned ade-
nylate drain. Thus, the HisHF enzyme is an attractive site for
the study of metabolic integration.
Due to the arrangement of the his genes within an operon
(Fig. 2A) (88), it is difficult to eliminate function of an indi-
vidual gene due to the polar nature of many his mutations.
Furthermore, draining of adenylates by such mutants might
* Corresponding author. Mailing address: DuPont Company, Cen-
tral Research and Development, Biochemical Science and Engineer-
ing, Experimental Station, P.O. Box 80173, Wilmington, DE 19880-
0173. Phone: (302) 695-9264. Fax: (302) 695-9183. E-mail: Robert.A
.LaRossa@usa.dupont.com.
† Present address: Department of Biology, Swarthmore College,
Swarthmore, PA 19081-1390.
3353
provide a strong selective pressure for true reversion or pseu-
do-reversion. Hence, the ability to transiently compromise
HisHF or HisA activity by the addition of a specific inhibitor is
desirable. We demonstrate that acivicin has such HisHF-di-
rected antagonism. The nutrients that prevent its inhibitory
action, its specificity, and the consequences of its administra-
tion are investigated by the genetic, biochemical, and enzymo-
logical analyses of E. coli reported here.
MATERIALS AND METHODS
Abbreviations and nomenclature. Standard bacterial nomenclature (8) is used.
Biosynthetic intermediates are abbreviated as follows: PRFAR, N1-[(59-phospho-
ribulosyl) formimino]-5-aminoimidazole-4-carboxamide ribonucleotide; IAP,
imidazole acetol phosphate; HOL-P, L-histidinol phosphate; HOL, L-histidinol;
and 2-KG, 2-ketoglutarate. Polypeptide nomenclature includes HisG (ATP
phosphoribosyl transferase), the HisI (the bifunctional phosphoribosyl-ATP py-
rophosphorohydrolase/phosphoribosyl-AMP cyclohydrolase), the HisH (glu-
tamine amidotransferase) domain, the HisF (cyclase) domain, HisB (the bifunc-
tional IGP dehydratase/HOL-P phosphatase), HisC (HOL-P aminotransferase),
HisD (histidinol dehydrogenase), and YIP (yeast inorganic pyrophosphatase).
Chemicals and biochemical reagents. Acivicin, glutamine, PRPP, and yeast
inorganic pyrophosphatase were purchased from Sigma (St. Louis, Mo.). Purified
E. coli HisHF enzyme (0.4 mg/ml, 7 U/mg) was a gift from V. J. Davisson, Purdue
University.
Strains and plasmids. Plasmids are described in Table 1. E. coli strains FB1
(DhisGDCBHAFI750) (12) and FB1/phisAGIE-tac were obtained from V. J.
Davisson. The set of his operon point mutants was obtained from P. E. Hartman
and has been described previously (30, 31). Salmonella enterica serovar Typhi-
murium Tn10 mutations were backcrossed into the wild type, selecting for tet-
racycline resistance as described elsewhere (20).
Inhibition assays. Disk diffusion was performed as described for sulfometuron
methyl (47, 50), a modification of a previously described scheme (75). An alter-
native bioluminescent technique was also used (26). Briefly, an insertion of a
recA promoter-Photorhabdus luminescens luxCDABE fusion within lacZ was
crossed into strain DPD1692, selecting for kanamycin resistance. This strain,
DPD1718, produces a high, baseline bioluminescence that is induced by DNA-
damaging agents (82) and dampened by a wide range of metabolic inhibitors
(11). Details of the construction have been described elsewhere (25). Both
techniques are amenable to auxanography, a means to determine the pathway
blocked by either mutation (20) or inhibitor action (47) through the supplemen-
tation with pools of nutrients. This method was used to determine those nutrients
that allow metabolic function, be it growth or bioluminescence, in the presence
of the inhibitor.
The ability of plasmids to alter the response to acivicin was also assayed using
a bioluminescence-based protocol. Transformants (59) of strain DPD1718 har-
boring either pUC18 or pDEW327 were obtained by selecting for resistance to
ampicillin (100 mg/ml) on Luria-Bertani plates (20). Single-colony isolates were
inoculated into minimal E medium supplemented with thiamine, 0.4% glucose,
and 100 mg of ampicillin per ml and incubated overnight at 37°C. Cultures were
diluted into a modification of this medium that contained 50 instead of 100 mg
of ampicillin per ml and shaken until they reached the exponential phase of
growth. They were then exposed to acivicin in microtiter plates, and the response
was monitored as a function of time using a standard method as published (79)
except that the microtiter plates were incubated in a luminometer chamber
maintained at 37°C. The resultant kinetic curves (data not shown) indicated that
acivicin blocked luminescence shortly after its administration. This blockage was
transient if the medium was supplemented appropriately or if the genetic con-
stitution titrated out inhibitory effects. For simplicity, an endpoint, a modified
response ratio (7, 79) obtained at 400 min, was calculated from the difference in
luminescence obtained after treatment with a given concentration of acivicin for
this time period divided by the difference in luminescence obtained with an
untreated sample.
Genetic titration and complementation. The method used has been described
in general for E. coli (15). The specific plasmid libraries containing random
segments of the E. coli W3110 genome have been described (26) and used (87;
Z. Xue, D. R. Smulski, D. Delduco, S.-Y. Soon-Yong Choi, M. H. Jia, and R. A.
LaRossa, unpublished data) elsewhere. The MIC of acivicin for strain DPD1675
was 1 mg/ml on E (20) minimal agar medium supplemented with 0.2% glucose,
thiamine, and proline. Selection was for those few transformants (59) of
pBR322- and pUC18-based genomic libraries of E. coli that would support
growth on the above-described medium supplemented with ampicillin (100 mg/
ml) and acivicin (3 mg/ml). Plasmid DNA was isolated from resistant clones,
backcrossed by transformation (59) into strain DPD1675 to ascertain that resis-
tance was a plasmid-specified phenotype, and sequenced as described previously
(26, 87; Xue et al., unpublished).
Similarly, hisA and hisH mutants were transformed with the same libraries with
selection for ampicillin-resistant prototrophs. In a like manner, the his-comple-
menting plasmids were backcrossed as well as being transformed into a broad set
FIG. 1. Structures of some amino acids. Only R groups are de-
picted.
FIG. 2. (A) The histidine operon. his genes are indicated by boxes.
Promoters are indicated by filled dots with arrows denoting direction
of transcriptions. Sites of transcriptional termination are denoted by
lollipops. (B) Plasmids that complement his point mutants, denoted by
lines.
FIG. 3. Histidine biosynthesis. Also shown is the reaction (b) cat-
alyzed by yeast inorganic pyrophosphatase that drives reaction a to the
right in a coupled in vitro system.
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of his point mutants. The extent of chromosomal DNA carried on each plasmid
was determined by complementation of auxotrophs and sequencing the vector-
chromosome junctions.
Substrate preparation. PRFAR was synthesized using E. coli strain FB1/
phisAGIE-tac based on published protocols of Davisson et al. (21) and Deras
(22), with some modifications. The reaction scheme is shown in Fig. 3. PRPP
(270 mmol) was reacted with excess ATP (400 mmol) in the presence of 72 U of
inorganic pyrophosphatase and 9.6 mg of FB1/phisAGIE-tac extract in 86 mM
potassium phosphate (pH 7.5)–28 mM MgCl2–3.5 mM EDTA. After the reaction
flask was shaken at 30°C for 1 h, an additional 4.8 mg of FB1/phisAGIE-tac
extract was added, and the reaction mixture was incubated for another 2 h.
PRFAR was purified by applying the reaction mixture to a Q-Sepharose column
(2.5 by 14 cm; Pharmacia) equilibrated with 60 mM NH4HCO3, and eluting with
an NH4HCO3 gradient (60 to 300 mM over 300 ml). The fractionated eluant was
analyzed by UV-visible light spectroscopy, and fractions in which A290/A260 was
.1.0 were pooled and dried by lyophilization. The lyophilized product was
redissolved in 0.1 M tetraethylammonium acetate (pH 7.0) and further purified
by reverse-phase high-pressure liquid chromatography on a C18 column (Supelco
LC18 column; preparative scale; 2.5 by 25 cm). PRFAR was eluted isocratically
by 0.1 M tetraethylammonium acetate, monitored by optical density at 300 nm.
Peak fractions containing PRFAR were pooled, lyophilized, and stored at
280°C. Purified PRFAR was analyzed by UV-visible light spectroscopy and gave
characteristic absorbance peaks at A220 and A300.
HisHF enzyme assay. The standard assay for E. coli HisHF (55) was per-
formed as described elsewhere (45). The assay basis is the initial rate of substrate
PRFAR disappearance as monitored by A300. Briefly 100 mM PRFAR is mixed
with 5 mM glutamine in 50 mM Tris-HCl (pH 8.0), and the reaction is initiated
by addition of purified HisHF at 0.02 U/ml (62 nM). The mixture was incubated
at 25°C for 2 to 5 min. One unit of activity is defined as formation of 1 mmol of
product per minute under the specified reaction conditions.
Ki determination. To determine the inhibition constant (Ki) for acivicin, the
HisHF assay was performed in the presence of 400 or 625 nM acivicin at
glutamine concentrations of 0.125, 0.25, 0.5, 1, and 2 mM. The Ki for acivicin was
determined from the reciprocal plot of 1/V versus 1/[glutamine].
HisHF inactivation by acivicin. HisHF (1.0 mM) was preincubated at 25°C in
100 ml of 50 mM Tris-HCl (pH 8.0) with (i) 10 mM acivicin, (ii) 100 mM PRFAR,
(iii) 10 mM acivicin and 100 mM PRFAR, and (iv) buffer only. An aliquot (12 ml)
was removed at 0, 10, 20, 40, and 60 min and diluted into a reaction mixture (288
ml) containing 100 mM PRFAR, 5 mM glutamine, and 50 mM Tris-HCl (pH 8.0),
and the initial rate of the reaction was measured as described above.
Gene expression profiling. The basic dual-label, fluorescence-based method
has been described in detail elsewhere (86). These experiments differed from
those described previously in that the genes were spotted at a higher density, i.e.,
9,000 spots/per slide, using a generation III DNA spotter (Molecular Dynamics,
Sunnyvale, Calif.) such that an entire genome was spotted in duplicate on a single
slide, negating the need for slide-to-slide correction. Genes were categorized into
the functional groups of Riley and Labedan (67) as has been used in other
transcript profiling exercises (85, 86).
RESULTS AND DISCUSSION
Nutritional supplementation. Acivicin inhibited the growth
of many E. coli K-12 and S. enterica serovar Typhimurium
strains when grown on solidified minimal, but not rich, media.
The presence of histidine or purines (guanine plus adenine),
but not tryptophan, glutamate, or glucosamine-6-phosphate,
significantly lessened the inhibition as monitored by disk dif-
fusion assays (data not shown) with E. coli strain CS1562 (69)
and S. enterica serovar Typhimurium strain TV101. Similar
results were obtained when nutrient pools were used in aux-
anography (20) with a bioluminescent tester strain, DPD1718
TABLE 1. Strains and plasmids used
Strain or plasmid Genotype Source (reference)
E. coli
CS1562 F2 l2 tolC::mini-Tn10 supE42 rph-1 C. Schnaitman (5)
DPD1675 ilvB2101 ara thi D(proAB-lac) tolC::mini-Tn 10 Lab strain (80)
DPD1692 lac Kanr Lab strain (17)
DPD1718 lac Kanr lacZ::recAfluxCDABE Lab strain (17)
FB1 DhisGDCBHAFI750 V. J. Davisson (12)
hisG2243 hisG2243 PEH, JHUa (30)
hisG3857 hisG3857 PEH, JHU (30)
hisD921 hisD921 PEH, JHU (30)
hisC901 hisC901 PEH, JHU (30)
hisC904 hisC904 PEH, JHU (30)
hisB463 hisB463 PEH, JHU (30)
hisH4744 F2 hisH4744 nadB29 thi mtl xyl ara lac PEH, JHU (31)
hisA323 hisA323 PEH, JHU (30)
hisF860 hisF860 PEH, JHU (30)
hisF891 hisF891 PEH, JHU (30)
hisI903 hisI903 PEH, JHU (30)
MG1655 F2 l2 rph-1 D. Berg, Washington University (6)
RFM443 rpsL galK2 lacD74 Rolf Menzel (56)
S. enterica serovar Typhimurium
LT2 S. enterica serovar Typhimurium 1 K. Rudd, Miami
TT7542 S. enterica serovar Typhimurium relA21::Tn10 K. Rudd
TV101 S. enterica serovar Typhimurium rfa Lab strain (81)
LT2 relA S. enterica serovar Typhimurium relA21::Tn10 This study, P22 (TT7542) 3 LT2 3 Tetr
Plasmids
pBR322 Cloning vector 68
pDEW326 pUC18 1 his9BHAF9 This work
pDEW327 pUC18 1 his9BHAFI This work
pDEW335 pUC18 1 his9GDCBHAFI9 This work
phisAGIE-tac V. J. Davisson (21)
pUC18 Cloning vector 68
PVV101 pBR322 1 trpEDC9 C. Yanofsky, Stanford University
a PEH, JHU, Philip E. Hartman, Johns Hopkins University.
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(data not shown). The mixture of adenosine, histidine, phenyl-
alanine, glutamine, and thymine was completely effective at
preventing inhibition by acivicin, while supplementation with
histidine, lysine, and the three branched chain amino acids was
almost as effective an antidote. Other pools were incapable of
preventing the inhibitory action. Histidine alone was not quite
as effective an antidote as either mixture. This, together with
the structural similarity between acivicin and glutamine, sug-
gested that the target of acivicin in E. coli might be the HisHF
enzyme.
These results were somewhat surprising since acivicin has
been suggested to target other enzymes, notably glutamine ami-
dotransferases, including GMP synthetase (41, 54), CTP synthe-
tase (54), g-glutamyl transpeptidase (38), formylglycineami-
dine ribonucleotide synthetase (24), and carbamoyl phosphate
synthase (4), in mammalian and protozoan systems. Kis as low
as 2 (4) to 5 (24) mM and as high as 420 mM (38) have been
reported for these interactions.
Acivicin is a competitive inhibitor of glutamine for HisHF.
HisHF catalyzes the reaction of PRFAR and glutamine to
form of IGP, AICAR, and glutamate (88). The kcat of E. coli
HisHF is 8.5 s21, the Km for glutamine is 240 mM, and the Km
for PRFAR is 1.5 mM (45). We assayed the activity of HisHF
in the presence of 100 or 400 nM acivicin, with glutamine
concentrations ranging from 0.125 to 2 mM, while keeping
PRFAR at 100 mM, a vast excess. A reciprocal plot of 1/V
versus 1/[glutamine] was generated (Fig. 4), resulting in an
estimate of 290 mM for the glutamine Km. This value was
consistent with another determination noted above. Moreover,
the Ki of acivicin was determined to be 140 nM. This indicates
that acivicin is at least an order of magnitude more inhibitory
in vitro toward HisHF than those enzymes that have been
tested by others. Thus, acivicin was a potent inhibitor of HisHF
in vitro.
In a second experiment, HisHF activity was measured with
excess (5 mM) glutamine and various concentrations of PRFAR
(5, 12.5, 25, and 50 mM) in the presence or absence of 400 nM
acivicin. No difference in the initial HisHF reaction rate was
observed in the presence of the inhibitor (data not shown).
This indicated that acivicin was a competitive inhibitor of glu-
tamine, but not PRFAR, binding to HisHF.
The inactivation of HisHF by acivicin is accelerated by
PRFAR. A possible mechanism of acivicin action is that it binds
competitively to the glutamine binding site on HisH and inac-
tivates the enzyme by covalent modification of an active site
cysteine residue essential for glutamine amidotransferase activ-
ity. HisH and HisF of E. coli are isolated as a single hetero-
dimer (45). It thus is possible that both the glutamine amido-
transferase activity of HisH and the cyclase activity of HisF are
carried out at one active site shared between the two polypep-
tides and that the binding of glutamine and PRFAR is coop-
erative. A second possibility is that separate substrate binding
sites exist on the HisH and HisF polypeptides. After the glu-
tamine amidotransferase reaction is carried out on the HisH
domain, NH3 might be transferred to the PRFAR binding site
on the HisF domain. To test this hypothesis, acivicin was used
to probe the active site of HisHF together with PRFAR. HisHF
was preincubated with 10 mM acivicin alone (1:10 ratio of en-
zyme to inhibitor), 100 mM PRFAR alone (1:100 ratio of en-
zyme to substrate), or both 10 mM acivicin and 100 mM PRFAR.
The preincubation time varied from 0 to 60 min. At each time
point, an aliquot of the mixture was removed and assayed for
remaining activity. The fraction of residual activity was plotted
versus preincubation time (Fig. 5). In the presence of either
acivicin or PRFAR alone, there was a time-dependent loss of
HisHF activity. This indicates that both acivicin and PRFAR
were irreversible inhibitors of the reaction when incubated
with HisHF alone. It is rather interesting that PRFAR inhib-
ited the reaction irreversibly when it was added to the enzyme
before the addition of glutamine. Even more interesting, when
both acivicin and PRFAR were preincubated with HisHF, the
enzyme activity at the first time point (10 min) decreased
dramatically to almost the background level. We have not yet
investigated if inactivation is more than additive. In addition,
binding of PRFAR to the active site may promote covalent
FIG. 4. Inhibition of E. coli IGP synthase (HisHF) by acivicin.
FIG. 5. Inactivation of E. coli IGP synthase (HisHF) by acivicin
(triangles), PRFAR (diamonds), and acivicin plus PRFAR (open cir-
cles). The untreated enzyme is indicated by closed circles.
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bond formation between glutamine and the catalytic cysteinyl
residue of the HisH domain. These results were consistent with
the proposed catalytic mechanism (66) and our hypothesis that
the HisH domain and HisF domain share one active site that
carries out both the glutamine amidotransferase and cyclase
steps of the reaction. Moreover, they raise the possibility that
the dominant factor contributing to the growth inhibition of a
variety of microbial and eukaryotic cells could be the inactiva-
tion rates of various glutamine amidotransferases by acivicin as
well as each enzyme’s Ki for the small molecule.
Reconstruction experiments. Several salient features of his
operon expression must be noted to aid in the interpretation of
the following experiments. Three promoters (12) (Fig. 2A) are
present in the operon although the primary promoter (hisp1) is
more than 10-fold stronger than hisp2, which in turn is far
stronger than hisp3. Furthermore, transcription from hisp1
occludes usage of hisp2 (88). Initiation at hisp1 is stimulated by
the product of RelA, ppGpp (89), produced in response to
starvation for any amino acid (13). Transcriptional read-
through past att (43), the attenuator site, occurs when the in
vivo level of histidyl-tRNAhis is low (88). Thus, the operon is
subject to both global and specific regulatory circuitry.
Plasmids capable of complementing hisA and hisH mutants
were found by selecting for prototrophic recombinants after
transformation with genomic libraries. The vector junctions
with the chromosomal inserts were determined by sequencing.
These results are summarized in Fig. 2B.
The following experiments were performed with the se-
quenced plasmids (Fig. 2B) to corroborate the presumption
that HisHF was the primary target of acivicin within E. coli.
Two micrograms of acivicin created a zone of inhibition with a
diameter of 38 6 3 mm (n 5 2) on the control strain. RFM443/
pBR322. Strain RFM443/pUC18 yielded a zone of 34 6 0 mm
(n 5 2). Strain RFM443/pDEW335 (his9GDCBHAFI9) had a
greater tolerance; its zone of inhibition was 19 6 1 mm.
RFM443/pDEW327 (his9BHAFI9) was somewhat tolerant,
having a zone of 27 6 0 mm (n 5 2) while RFM443/pDEW326
(his9BHAF9) was sensitive, displaying a diameter of 42 6 2 mm
(n 5 2). pDEW335 (his9GDCBHAFI9) contains the nonoc-
cluded hisp2 promoter, while the other two his plasmids lack
this internal promoter. Further, pDEW326 (his9BHAF9) can-
not specify an increased content of IGP synthase since only
HisH and HisA polypeptides can be elevated. Thus, elevated
expression of HisH, HisA, and HisF was sufficient for devel-
opment of an acivicin-tolerant phenotype. Amplification of the
trp control region, trpE and trpD expressing the two subunits of
another glutamine amidotransferase, anthranilate synthase,
did not result in tolerance; strain RFM443/pVV101 (trpEDC9)
displayed a diameter of 39 6 4 mm (n 5 2). This result
suggests that a glutamine amidotransferase cannot protect
cells by simply acting as a macromolecular sponge (49) absorb-
ing acivicin. Thus, amplification of the genes specifying the
histidine biosynthetic glutamine amidotransferase, HisHF,
conferred tolerance to the inhibitory agent.
This result was further confirmed with a bioluminescence
experiment (Fig. 6). A plasmid expressing only HisH, HisA,
and HisF (pDEW327) and a control vector (pUC18) were
placed in a bioluminescent E. coli strain, DPD1718. The biolu-
minescence of each recombinant was titrated with acivicin. The
response ratio obtained 400 min after the administration of
acivicin was plotted as a function of inhibitor concentration. As
can be seen from Fig. 6, much more acivicin was needed to
inhibit bioluminescence from the strain in which hisHAF was
amplified, again suggesting that HisHF was the primary target
of acivicin. The protection afforded by hisHAF amplification
was similarly supplied by supplementation with L-histidine
(Fig. 6; compare the curve of the control strain treated with
L-histidine to that of the strain carrying the hisHAF amplifica-
tion in the absence of L-histidine). Evidence for L-histidine
supplementation enhancing the protective effect of hisHAF
amplification was not obtained (Fig. 6); such effects strongly
indicate that HisHF or HisA was the in vivo target of acivicin.
Genetic titration. Libraries of random fragments of the
E. coli genome in either pUC18 or pBR322, harbored in strain
DPD1675, served as a source of genetic variation. Clones re-
sistant to acivicin were selected, plasmids conferring the resis-
tance phenotype were sequenced, and the precise locations of
the resistance elements were thus determined. These resis-
tance elements mapped to two regions distinct from his.
Nine plasmids mapped to one of these regions (9). Although
each encompassed several genes in this region (Fig. 7), only a
single gene, yedA, was present in each plasmid. The function of
this gene has not yet been described, although homology to the
PecM protein of Erwinia chrysanthemi (E value of 7e-19) has
been noted by computational searches (1, 2). yedA is predicted
to encode an integral membrane protein with nine regions
spanning the lipid bilayer. It is tempting to speculate that
YedA is a component of an acivicin export system.
FIG. 6. Titration of a bioluminescent response by acivicin. The bio-
luminescent host strain DPD1718 was transformed with either pUC18
or pDEW327. Squares, the strain contained pUC18 and the medium
was not supplemented with histidine; diamonds, the strain contained
pUC18 and the medium was supplemented with histidine; crosses, the
strain contained pDEW327 (his9BHAFI) and the medium was not
supplemented with histidine; triangles, the strain contained pDEW327
(his9BHAFI) and the medium was supplemented with histidine.
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One other plasmid, mapping to a different region and con-
taining intact sequences of iciA and yqfE, a divergently tran-
scribed pair of genes, conferred resistance to acivicin (Fig. 8).
Neither iciA nor yqfE alone resulted in an acivicin-resistant
phenotype (data not shown). The function of yqfE is unknown,
while those of IciA have been defined by in vivo and in vitro
studies. IciA is a DNA binding protein that is a member of the
LysR family of transcriptional regulators (76). It binds to a set
of three double-stranded 13-mers within oriC, the origin of
chromosomal replication. Such binding apparently antagonizes
the creation of a bubble in the double helix; that bubble,
stabilized by the specific binding to the same 13-mers in one
single strand, is a prerequisite for the initiation of DNA syn-
thesis (40). IciA is a pleiotropic regulator stimulating expres-
sion of nrd (33), dnaA (53), and perhaps other genes. More-
over, IciA in the presence of arginine inhibits its own synthesis
(14). iciA transcription is also positively regulated by PhoB
when phosphate is depleted (34). Further, IciA is a substrate
for proteolytic degradation by the htrA-encoded protease Do
(91), providing a mechanism in addition to its synthesis early in
the cell cycle (93) for its periodic pattern of accumulation.
Hence, amplification of a complex sensing system may confer
resistance to acivicin. The relationship between yedA and the
iciA region has not yet been addressed. Studies combining
chromosomal mutations in one region and amplification of the
second region on a multicopy plasmid may be informative.
Thus, amplification of three distinct genetic regions (two, yedA
and iciA-yqfE, defined by genetic titration and one, hisHAF,
proven by reconstruction) gave rise to acivicin resistance.
Gene expression profiling. The growth of E. coli strain
MG1655 in minimal medium with glucose as a carbon source
was inhibited about 80% by 0.5 mg of acivicin per ml; such
inhibition was completely prevented by coexposure to histi-
dine. Histidine also reversed a greater acivicin challenge (2
mg/ml, 90% inhibition); the culture exposed to both the antag-
onist and the antidote grew at about 90% of the uninhibited
rate (data not shown). Results from a representative DNA
microarray experiment, in which E. coli MG1655 was chal-
lenged with acivicin at 2 mg/ml in minimal medium for 60 min,
are presented in Tables 2 and 3. This treatment lowered the
growth rate by about 85%. The structural similarity among
acivicin, glutamine, and asparagine is illustrated in Fig. 1. This
similarity was reflected in the gene expression profile described
below.
Indications that acivicin serves as an imposter of certain
natural amino acids. Transcription of glnA, encoding gluta-
mine synthetase, was lowered more than sixfold. Expression of
asnS, coding for asparaginyl-tRNA synthetase, was decreased
more than fivefold; unfortunately, the spotted glnS PCR prod-
uct was of poor quality (Y. Wei and R. LaRossa, unpublished
data), precluding insight into its transcriptional response to aci-
vicin.
Evidence that HisHF is the major target in vivo. If the
HisHF enzyme is inhibited by acivicin in vivo, then transcrip-
tion should initiate frequently at the his promoter (75, 89), pass
through the leader/attenuator (43), and traverse the structural
genes. This expectation was indeed realized, as the eight struc-
tural genes, hisGDCBHAFI, and the leader hisL were up-reg-
ulated 6- to 16-fold by administration of 2 mg of acivicin per ml.
Ranking of open reading frames (ORFs) by fold induction with
acivicin placed his operon genes in the 4th (hisC), 5th (hisL),
6th (hisB), 7th (hisI), 8th (hisG), 9th (hisD), 11th (hisH), 12th
(hisF), and 28th (hisA) positions.
Metabolic mayhem. The term “metabolic mayhem” has been
applied to the action of sulfonylurea herbicides in S. enterica
serovar Typhimurium, which causes the cell to (i) signal me-
thionine sufficiency (10) in the face of methionine limitation
(51) and (ii) skew the ratios of 2-ketoacids (52) and acyl co-
enzyme A’s (78), two classes of central precursor metabolites.
Together, about 60% of the organic content of E. coli is de-
rived from these two sets of central building blocks (48). A
similar case may be evident when HisHF activity was limiting.
The ATP pool was compromised (29, 42). The cell, however,
FIG. 7. yedA region of the E. coli chromosome. Lines below the map show the extents of various plasmids that confer acivicin resistance.
Directions of transcription are indicated by arrowheads on symbols denoting genes; dots indicate promoters.
FIG. 8. iciA region of the E. coli chromosome, denoted as de-
scribed for Fig. 7.
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TABLE 2. Transcripts induced by acivicin treatment
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did not respond by elevating the F0-F1 ATP synthase-specify-
ing transcripts; rather, the atp operon was mildly repressed
(Table 3), indicating that the capacity to convert ADP to ATP
was not enhanced. Most purine biosynthetic transcripts were
not affected appreciably by the acivicin administration, sug-
gesting that the PurR regulon (92) was indifferent to this treat-
ment. Evidence for modulating expression of two purine-re-
lated operons, however, was found. The bicistronic guaBA
operon was down-regulated about twofold (Table 3), while the
purA transcript was elevated more than sevenfold (Table 2).
The latter result contradicted the thought (37) that the PurR-
independent regulation of purA is posttranscriptional. Both the
purA and guaBA operons are regulated by multiple regulatory
circuits (92). guaBA is responsive to PurR (92), cyclic AMP
receptor protein (39), and DnaA (92), while purA is controlled
by both PurR and an adenine-dependent mechanism (92).
These transcriptional data suggested that flux from IMP to
AMP was being encouraged at the expense of forming GMP
from the common intermediate IMP. Thus, the apparent in-
consistencies in the transcriptional regulation of the purine
regulon might be indicative of a baroque regulatory mecha-
nism designed to maintain balance between the GTP and ATP
pools.
Acivicin triggers the stringent response. The just-mentioned
induction and repression of gene expression suggest that the in
vivo levels of histidyl-tRNA, glutaminyl-tRNA, and/or aspar-
aginyl-tRNA may be lowered by acivicin treatment. Any such a
drop would trigger the stringent response. This response has
two basic elements, conservation of amino acid reserves by
shutting off synthesis of ribosomes and other translational ma-
TABLE 3. Transcripts repressed by acivicin treatment
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chinery (13) and a redirection of resources toward increasing
amino acid biosynthesis (75, 89). Aspects of each are apparent
in the gene expression profile of acivicin-treated cells. As ex-
pected for a treatment resulting in amino acid starvation, ex-
pression of the translational apparatus was decreased; 49 dis-
tinct ORFs encoding proteins involved in translation were
down-regulated by a factor of 2 or more (Table 3).
Evidence for elevation of amino acid biosynthetic capacity
was also found (Table 2). Seven arg genes were induced three-
to ninefold by this treatment. Also highly induced were bio-
synthetic genes corresponding to the aspartate-derived family
of amino acids. The gene, aspC, specifying the major transam-
inase responsible for aspartate formation was elevated eight-
fold. The leader transcript of the thr operon was elevated
sevenfold, while expression of five met ORFs was enhanced
two- to sixfold. Acivicin exposure also induced the lysine syn-
thesis-involved dapB mRNA by a factor of 5. This subdivision
of induced transcripts by metabolic origin of amino acids is
unexpected. It suggests, moreover, that the global response to
amino acid starvation may be more complex than suggested by
current dogma or that acivicin’s targets include factors other
than HisHF.
In contrast, transcription of only a single amino acid trans-
port gene, mtr, was elevated (Table 2). This elevation, by a
factor of 21, was dramatic; mtr was the third most highly in-
duced gene. Amino acid transport had been suggested to be
under stringent control (13), based primarily on studies of
branched chain amino acid transport (63). That suggestion
may need to be reevaluated in light of these findings. The
reported pleiotropic effects of the stringent response are quite
broad (13). The transcriptional responses elicited by other
amino acid antagonists as well as the dependence of these
responses on relA will further define this regulon.
Other stress responses triggered by the acivicin challenge.
The two most highly induced genes were hslS and hslT, heat
shock loci (65), whose transcripts were elevated 20- to 30-fold
(Table 2). Other stress-responsive transcripts (Table 2) were
highly induced, including clpB (8.6-fold), appA (4.3-fold), uspA
(4.2-fold), ahpC (3.4-fold), rpoH (3.2-fold), slp (3-fold), rob
(2.8-fold), cspE (2.8-fold), soxS (2.8-fold), htpX (2.6-fold),
osmE (2.6-fold), sugE (2.5-fold), grpE (2.5-fold), sohA (2.4-
fold), and slyD (2.1-fold). Also within this group of induced
mRNA species were transcripts involved in osmotolerance,
including betT (8-fold), otsA (4.4-fold), betI (4.3-fold), osmY
(3.8-fold), otsB (2.7-fold), osmE (2.6-fold), treF (2.4-fold), betA
(2.4-fold), and betB (2.4-fold). Expression of some genes in-
volved in DNA and RNA metabolism was also heightened;
elevated levels of hepA, rna, nfo, recN, and xseB transcripts
were observed.
Expression of genes involved in iron metabolism was also
elevated by acivicin treatment. Induced genes included ftn (11-
fold), bfr (6.4-fold), and entE (2.7-fold). Transcripts of cydA,
frdB, frdC, nrdD, nrdG, nrdH, nrdI, qor, and torD, involved in
respiratory activity, were also elevated. Cause and effect are
difficult to separate. The implied increase in iron metabolism
could elevate the superoxide content, as suggested by the in-
creased soxS mRNA titer. Such puzzles, as well as that involv-
ing the interplay between acivicin and respiration, await fur-
ther study.
Unanticipated repression by acivicin. Many changes were
observed that were not predictable. Strikingly, the level of
several amino acid biosynthetic transcripts was not up-regu-
lated but rather reduced by histidine starvation (Table 3),
including transcripts for genes specifying components of the
aromatic pathways (aroA, aroF, aroH, pheA, trpL, and tyrB), the
pyruvate family (avt, ilvB, ilvC, ilvD, ilvE, ilvG, ilvM, leuC, and
leuD), sulfur amino acids (cysA, cysC, cysD, cysK, cysM, cysN,
and metE), and the aspartate family (lysC). Greater than five-
fold repression was observed for aroA, ilvC, ilvG, and metE.
Each of these genes is distinctive; aroA (16) and ilvG (47)
specify enzymes targeted by commercially important herbi-
cides, while ilvC and metE encode enzymes that must be highly
expressed (86) due to their poor performance as catalysts (32,
60, 90). Interestingly, expression of another most highly ex-
pressed, pyrimidine biosynthetic operon (86) was down-regu-
lated by the acivicin challenge; pyrBI (specifying aspartate tran-
scarbamylase) transcripts were greatly reduced. Surprisingly,
genes implicated in uptake of amino acids or their precursors
were often down-regulated. Included in this category were
cysP, livJK, and proX. Certain carbon utilization transcripts
were down-regulated. Repression of six gat and three uid genes
was observed.
Like the data concerning expression of amino acid permease
systems in response to acivicin treatment discussed earlier, the
unexpected and strong repression of many highly expressed
biosynthetic genes by acivicin treatment suggests that the re-
sponse to amino acid starvation is not a uniform induction of
appropriate defenses. Rather, the cellular logic appears to be
more selective; the cost of synthesizing a poor catalyst like IlvC
or MetE may outweigh the benefits associated with their ac-
tion. Thus, we are surprised that the decision to correct the
perceived imbalance or to wait for the insult to pass may be
made on a gene-by-gene basis.
Unanticipated elevation of gene expression by acivicin ad-
ministration. Expression of three genes, ack (78), pta (78), and
mrp (D. R. Smulski and R. A. LaRossa, unpublished data),
whose inactivation leads to a sulfometuron methyl-sensitive
phenotype in S. enterica serovar Typhimurium LT2 (52), was
elevated after acivicin treatment. Other transcripts increased
by this treatment were specified by the tdh-kbl operon. The
corresponding gene products specified by this operon degrade
threonine to pyruvate and ammonia through glycine and se-
rine. Thus, the overall pathway involves tdh, kbl, gcvTHP, lpdA,
glyA, and sdaA or metC (64). The lpdA and sdaA mRNA titers,
as well as the tdh-kbl transcript levels, were elevated by acivicin
treatment, suggesting increased flux through this pathway.
Summation. Acivicin is a natural product produced by strep-
tomycetes. Its ecological role may be to defend the home turf
of the producing species, encouraging other microbes to emi-
grate toward less hostile environments. Such use in antibacte-
rial warfare may be explained by theories concerning the evo-
lution of translation (18, 19) and biosynthetic pathways. Hence,
adoption of acivicin for use in cancer therapy represents its
introduction into a novel niche, one occupied by cells lacking
its intended target, HisHF. Thus, studies of the action of acivi-
cin with other glutamine amidotransferases could represent
more general aspects of the binding of glutamine to the amido-
transferase enzyme family. In contrast, acivicin interacted much
more avidly with HisHF from E. coli. This specific interaction
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is not limited to the E. coli enzyme; inhibition of the homolo-
gous eukaryotic enzyme, His7 from yeast, has been found (M.
McCluskey and L. Huang, unpublished data). The relative
contributions of acivicin’s competition with glutamine and its
inactivation of glutamine amidotransferases to the observed in
vivo effects are worthy of further study.
That acivicin was targeted toward HisHF in vivo was dem-
onstrated in several ways. Nutritional reversal of acivicin action
by inclusion of histidine in the test medium was most sugges-
tive. Amplification of the hisHAF portion of the histidine oper-
on resulted in a resistance phenotype, also supporting the pre-
sumption that HisHF was the in vivo target. Finally, the gene
expression profiling demonstrated that the cell was limited for
histidine. Such starvation can both drain adenylates and limit
histidyl-tRNA formation. In analogy to the detailed physiolog-
ical and genetic studies of sulfometuron methyl action (48, 52),
separation of these two consequences can be accomplished by
determining the acivicin-induced change in the transcriptional
profile of a feedback-insensitive hisG mutant grown in the pre-
sence of histidine. Given these results, it was somewhat surpris-
ing that a hisHAF-containing plasmid was not obtained from
the multicopy libraries when acivicin resistance was used as a
genetic selection. The large (.7-kbp) size of the operon may
have contributed to this failure to obtain the expected result.
Alternatively, the attenuation mechanism, unlike that of re-
pression, may not be titrated out by the presence of the his
operon on a multicopy plasmid.
Thus, several sorts of experiments were brought to bear on
the interaction of E. coli and acivicin. Collectively, they sup-
ported the conclusion that acivicin inhibited HisHF while sug-
gesting an intricate interaction between cell and inhibitor.
Much of the gene expression profile could be understood by
reference to the vast, preceding study of E. coli physiology.
Without combining such knowledge with the realization that
acivicin is a mimic of the natural amino acid L-glutamine,
interpretation would be more difficult. Since inhibitor binding
does not have to coincide with enzyme active sites, such mim-
icry may not always be as obvious as in the case of acivicin.
Thus, we suggest that a multifaceted approach to inhibitor
action remains the most likely path to definition of macromo-
lecular targets. Especially informative may be the selection of
missense mutants having a resistance phenotype; this approach
has defined both inhibitor targets and the means by which
these compounds are imported into the cell (46).
In addition, the gene expression profile also suggested sev-
eral novel regulatory circuits. Each of these is worthy of further
study. Two examples are noted. Transcripts of more than 150
genes of unknown function were elevated by exposure to acivi-
cin; the dependence of these changes on various global regu-
latory mechanisms can be readily evaluated. The massive and
apparently selective loss of highly expressed transcripts upon
treatment is also provocative. Moreover, this global view sug-
gested that the mRNA population is dramatically remodeled in
response to acivicin. This unanticipated remodeling indicates
that gene expression profiling will become a most important
means for uncovering the pleiotropic responses to inhibitor
action. Thus, comprehensive transcript profiling is an impor-
tant tool for the biological detective; its findings, however,
must be vigorously pursued by other methodologies if their
authenticity is to be established.
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